Bristol-Myers Squibb has rebounded strongly in 2024, driven by key drug approvals and positive financial performance. See why ...

BMS-986484 is under clinical development by Bristol-Myers Squibb and currently in Phase I for Non-Small Cell Lung Cancer.

Zolacabtagene autoleucel is under clinical development by Bristol-Myers Squibb and currently in Phase I for Marginal Zone B-cell Lymphoma.

Carolina Blue Bristol with handler Chris Speer finished first with a score of 875 after Friday night's hunt at the Grand ...

In March 2023, it was announced that long-serving Connacht scrum-half Kieran Marmion would be switching Galway for Bristol, ...

New Jersey’s unemployment rate was 4.6% in November, the latest figures available from the U.S. Bureau of Labor Statistics, a ...

GoodBoy Dog Recovery captured a wolf-dog hybrid spotted in Bristol after it managed to evade both animal control and the ...

Stagnant sales for Bristol Myers Squibb’s Sotyktu have ... let alone the $4 billion peak sales projected by the New Jersey drugmaker. Much will depend on how many indications the company can ...

Century Therapeutics entered the partnership three years ago. Bristol Myers Squibb is ending its drug development partnership with Philadelphia cell therapy company Century Therapeutics, a deal ...

BRISTOL, Pa. (WPVI ... The wolf-dog was taken to Howling Woods Farms in New Jersey and is doing well.

READ MORE: 'It’s the mature decision' - Bristol Bears bring in ... as their primary options in the 15 jersey for the rest of the season. Lane signed a new contract with the Bears late in the ...